Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06430385 · ClinicalTrials.gov registry record · Phase 1
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
A Phase 1 study of Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 10
- Study locations
NCT06430385 is a Phase 1 study of Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 48 participants. The trial reports 10 study locations across 9 states.
The verdict
NCT06430385, a Phase 1 study of Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
Conditions Studied
Interventions
- PROCEDURE Sham procedure
- DRUG ION440
Study Locations (10)
Other
- Kepler University Hospital - Linz
- CHU Dijon Bourgogne - Dijon
California
- Rady Children's Hospital - San Diego
Colorado
- University of Colorado Hopsital - Anschutz Medical Campus - Aurora
Maryland
- Kennedy Krieger - Baltimore
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- Gillette Children's Specialty Healthcare - Saint Paul
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06430385
The ClinicalTrials.gov registry entry for NCT06430385 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Sham procedure is the first listed.
NCT06430385 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06430385 about?
NCT06430385 is a clinical study titled "ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)". The primary purpose of this study is to evaluate the safety and tolerability of ION440.
What is the current status of trial NCT06430385?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-10-21. Estimated completion is 2030-04.
What conditions does trial NCT06430385 study?
This clinical trial studies the following conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome.
What interventions are being tested in trial NCT06430385?
The interventions under investigation include: Sham procedure (PROCEDURE), ION440 (DRUG).
Who is sponsoring clinical trial NCT06430385?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06430385 being conducted?
This trial has 10 study locations across California, Colorado, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.